相关实验视频
Updated: Jun 28, 2026
05:33
Three-Dimensional Shape Modeling and Analysis of Brain Structures
Published on: November 14, 2019
基于大脑形态变化的阿尔茨海默病早期诊断:一种综合方法,结合了基于voxel的形态测量和深度学习
Mohammad Rezaei1,2, Shaghayegh Mohammadikhaveh1, Hadis Faraji3
1Department of Biomedical Engineering, Tehran Azad University of Medical Sciences, Tehran, Iran.
Neuroimage. Reports
|January 21, 2026
概括
这项研究将生物特征与神经成像分析的深度学习相结合. 该方法通过分析轻度认知障碍 (MCI) 患者的大脑结构来增强早期阿尔茨海默病 (AD) 症状的检测.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 生物医学工程 生物医学工程
背景情况:
- 当前神经成像中的深度学习模型 (CNN,FCN) 往往缺乏生物解释性,重点关注统计模式而不是有意义的生物线索.
- 这种局限性对识别神经成像分析中的关键见解构成了重大挑战,特别是在阿尔茨海默病 (AD) 等疾病中.
研究的目的:
- 开发和验证一种新的深度学习方法,该方法集成了生物动机的功能,用于分析神经成像数据.
- 通过检查大脑结构特征,研究轻度认知障碍 (MCI) 患者的阿尔茨海默病早期症状.
主要方法:
- 集成的生物动机特征与基于voxel的形态学和深度学习模型 (CNNs,FCNs).
- 分析了T1加权的MRI和T2-Flair图像以提取生物标志物:白质超强度,灰质体积,白质体积,脑脊液 (CSF) 体积和皮质厚度.
- 通过将提取的生物特征转换成3位,4位,8位和16位图像以输入FCN和CNN模型来验证该方法.
主要成果:
- 综合方法成功地提取了反映神经退行变化的关键结构特征.
- 该方法通过从经过处理的神经成像数据中对内特征进行分类,证明了研究早期阿尔茨海默病症状的潜力.
结论:
- 将生物动机特征集成到深度学习模型中,提高了神经退行性疾病神经成像分析的解释性和有效性.
- 这种方法为早期检测和表征MCI和AD等疾病提供了有希望的途径.
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...